- Home
- KRMD vs IPHA Comparison
KRMD vs IPHA Comparison
Compare KRMD & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- IPHA
- Stock Information
- Founded
- KRMD 1980
- IPHA 1999
- Country
- KRMD United States
- IPHA France
- Employees
- KRMD N/A
- IPHA N/A
- Industry
- KRMD Medical/Dental Instruments
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- KRMD Health Care
- IPHA Health Care
- Exchange
- KRMD Nasdaq
- IPHA Nasdaq
- Market Cap
- KRMD 187.5M
- IPHA 150.9M
- IPO Year
- KRMD N/A
- IPHA 2019
- Fundamental
- Price
- KRMD $4.60
- IPHA $1.95
- Analyst Decision
- KRMD Strong Buy
- IPHA Strong Buy
- Analyst Count
- KRMD 5
- IPHA 1
- Target Price
- KRMD $4.50
- IPHA $11.50
- AVG Volume (30 Days)
- KRMD 157.7K
- IPHA 50.9K
- Earning Date
- KRMD 03-12-2025
- IPHA 03-20-2025
- Dividend Yield
- KRMD N/A
- IPHA N/A
- EPS Growth
- KRMD N/A
- IPHA N/A
- EPS
- KRMD N/A
- IPHA N/A
- Revenue
- KRMD $31,993,796.00
- IPHA $36,202,722.00
- Revenue This Year
- KRMD $20.04
- IPHA N/A
- Revenue Next Year
- KRMD $14.15
- IPHA $101.65
- P/E Ratio
- KRMD N/A
- IPHA N/A
- Revenue Growth
- KRMD 11.57
- IPHA N/A
- 52 Week Low
- KRMD $2.01
- IPHA $1.29
- 52 Week High
- KRMD $5.05
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- KRMD 66.80
- IPHA 56.50
- Support Level
- KRMD $4.16
- IPHA $1.72
- Resistance Level
- KRMD $4.40
- IPHA $1.92
- Average True Range (ATR)
- KRMD 0.23
- IPHA 0.11
- MACD
- KRMD 0.03
- IPHA 0.02
- Stochastic Oscillator
- KRMD 63.71
- IPHA 89.74
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.